5 Key Takeaways
-
1
Local steroids are a first-line treatment for uveitis, providing intraocular inflammation control without systemic immunosuppression.
-
2
Retisert, a fluocinolone acetonide implant, will be discontinued in April 2026 due to manufacturing difficulties, prompting patients to seek alternatives.
-
3
Triesence, a preservative-free triamcinolone acetonide injectable, faced a drug shortage but is set to relaunch in late 2024 with a significant price increase.
-
4
Yutiq, an injectable intravitreal insert, releases steroids for up to 36 months and is indicated for chronic noninfectious uveitis.
-
5
ANI Pharmaceuticals acquired Alimera Sciences, expanding Iluvien's label to include chronic noninfectious posterior uveitis, aligning it with European approvals.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
